Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Haematology

• Publication date

  2000-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2000.02419.xPMID 11122138
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.

  1999cited by this paper
• Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34+ Cells Using the CliniMACS Device

  1999cited by this paper
• Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients.

  1999influential reference
• CMV specific HLA-tetramer sorting of ex-vivo expanded CD8+CTL: Selection of highly restricted clonal populations suitable for adoptive cellular therapy.

  1999cited by this paper
• Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications

  1998cited by this paper
• Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis.

  1998cited by this paper
• Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture.

  1997cited by this paper
• Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease

  1997cited by this paper
• Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome.

  1997cited by this paper
• European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

  1996cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.

  1996influential reference
• Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.

  1996cited by this paper
• A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood

  1996cited by this paper
• Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.

  1996cited by this paper
• Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.

  1995influential reference
• A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.

  1995cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients

  1995cited by this paper
• Vitreous fluid sampling and viral genome detection for the diagnosis of viral retinitis in patients with AIDS

  1994cited by this paper
• Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients

  1994cited by this paper
• Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

  1994cited by this paper
• Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients

  1994cited by this paper
• Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones.

  1994cited by this paper
• Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.

  1994cited by this paper
• Cytomegalovirus viraemia and specific T‐helper cell responses as predictors of disease after allogeneic marrow transplantation

  1993cited by this paper
• Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

  1993influential reference
• Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind Trial

  1993influential reference
• EARLY DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS BY DNA AMPLIFICATION IN PLASMA

  1993cited by this paper
• Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients

  1992cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.

  1991cited by this paper
• A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

  1991cited by this paper
• A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants

  1991cited by this paper
• Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.

  1991influential reference
• Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor‐Derived CMV‐Specific T Cell Clones Expanded In Vitro a

  1991cited by this paper
• Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.

  1991cited by this paper
• Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique.

  1991cited by this paper
• RAPID DETECTION OF HUMAN CYTOMEGALOVIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES OF VIREMIC TRANSPLANT RECIPIENTS BY THE POLYMERASE CHAIN REACTION

  1989cited by this paper
• Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin.

  1988cited by this paper
• T CELL DEPLETION WITH CAMPATH‐1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION

  1988cited by this paper
• Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

  1988cited by this paper
• Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants.

  1988cited by this paper
• Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.

  1988cited by this paper
• Risk factors for cytomegalovirus infection after human marrow transplantation.

  1986cited by this paper
• Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience.

  1982influential reference

• Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques

  2024cites this paper
• Life-threatening Pneumocystis jiroveci pneumonia with cytomegalovirus coinfection in a follicular lymphoma patient during rituximab-based chemotherapy

  2024cites this paper
• American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation.

  2021cites this paper
• PCR analysis of CMV in hematology patients

  2021cites this paper
• Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

  2020cites this paper
• Antimicrobial Drug Prophylaxis: Challenges and Controversies

  2019cites this paper
• Selective T‐cell depletion targeting CD45RA reduces viremia and enhances early T‐cell recovery compared with CD3‐targeted T‐cell depletion

  2018cites this paper
• Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts

  2017cites this paper
• The Impact of Alemtuzumab Scheduling on Graft Versus Host Disease Following Unrelated Donor Fludarabine and Melphalan Allografts

  2017cites this paper
• Cytomegalovirus Infection After Stem Cell Transplantation

  2016cites this paper
• Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation

  2015cites this paper
• The roles of human cytomegalovirus tegument proteins pUL48 and pUL103 during lytic infection

  2015cites this paper
• Anti‐Infective Prophylaxis, Immunization and Prevention of Recurrent Infectious Complications in Long‐Term Survivors

  2013cites this paper
• Infectious Complications of Hematopoietic Stem Cell Transplantation

  2013cites this paper
• The significance of cytomegalovirus viremia at day 100 or more following allogeneic hematopoietic stem cell transplantation

  2013cites this paper
• [Prophylaxis against cytomegalovirus infection in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].

  2012cites this paper
• Transfusion and transplant safety

  2012cites this paper
• An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.

  2011influential citation
• [Diagnostic approach and therapy for cytomegalovirus (CMV) infection following allogeneic stem cell transplantation].

  2011cites this paper
• Cytomegalovirus in Patients with Cancer

  2011cites this paper
• Cytomegalovirus in hematopoietic stem cell transplant recipients.

  2011cites this paper
• [Comparison of new and old tests for the diagnosis of latent tuberculosis infection (quantiferon and TST)].

  2011cites this paper
• Cytomegalovirus in hematopoietic stem cell transplant recipients.

  2010cites this paper
• Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective

  2009cites this paper
• Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective.

  2009cites this paper
• The risk of early and late cytomegalovirus DNAemia associated with Campath use in stem cell transplant recipients

  2009cites this paper
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

  2009influential citation
• Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.

  2008cites this paper
• Viral diagnostics and antiviral therapy in hematopoietic stem cell transplantation.

  2008cites this paper
• reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem

  2008cites this paper
• Die Rolle von Zytokinkinetik im Vergleich zum Einfluss klinischer Risikofaktoren bei Aspergillose und CMV

  2008cites this paper
• Virological and immunological studies of human cytomegalovirus infection in allogeneic stem cell transplant recipients

  2008cites this paper
• Comparison of polymerase chain reaction of polymorphonuclear leukocytes and plasma identifies patients who control cytomegalovirus infection after hematopoietic cell transplantation.

  2008cites this paper
• Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies

  2007cites this paper
• Medical and psychosocial issues in transplant survivors

  2007cites this paper
• Selective Lymphopenia and Opportunistic Infections in Neuroendocrine Tumor Patients Receiving Temozolomide

  2007cites this paper
• Comparison of hybrid capture and reverse transcriptase polymerase chain reaction methods in terms of diagnosing human cytomegalovirus infection in patients following hematopoietic stem cell transplantation.

  2006cites this paper
• Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ⩾10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients

  2006cites this paper
• Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients.

  2005cites this paper
• Significance of qualitative PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation -- single-centre experience.

  2005cites this paper
• Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy

  2004cites this paper
• Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.

  2004cites this paper
• Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection

  2004cites this paper
• Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment.

  2004cites this paper
• Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma.

  2003cites this paper
• Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation

  2003cites this paper
• Human cytomegalovirus-associated periodontitis in renal transplant patients.

  2003cites this paper
• Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

  2003cites this paper
• Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

  2003cites this paper
• Influence of antithymocyte globulin dose on outcome in cytomegalovirus‐seropositive recipients of partially T cell‐depleted stem cell grafts from matched‐unrelated donors

  2003cites this paper
• Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival.

  2003cites this paper
• Measurement of CMV DNA Levels and CMV-Specific CD4+ Lymphocyte Counts in Patient Specimens: Requirements for Test Quality and Practicability in a Routine Diagnostic Service

  2003cites this paper
• T cell immunodeficiency and severe herpes virus infections after allogeneic stem cell transplantation

  2003cites this paper
• Evaluation des Cobas Amplicor CMV Monitor in der Diagnostik und Therapiesteuerung der HCMV-Infektion bei Patienten nach allogener Stammzelltransplantation

  2003cites this paper
• Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors.

  2002cites this paper
• High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

  2002cites this paper
• Development and evaluation of an internally controlled semiautomated PCR assay for quantification of cell‐free cytomegalovirus

  2002cites this paper
• Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

  2002cites this paper
• Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV.

  2002cites this paper
• Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient

  2002cites this paper
• Quantifizierung von CMV-DNA als diagnostisches Werkzeug zur verbesserten Behandlung und berwachung von Risikopatienten/CMV Genome Quantification as a Diagnostic Tool for Improving Treatment and Monitoring of Risk Patients

  2002cites this paper
• Performance characteristics of an automated PCR assay for the quantification of cytomegalovirus DNA in plasma.

  2002cites this paper
• Clinical trials with CMV-specific T cells.

  2002cites this paper
• Clinical utility of viral quantification as a tool fordisease monitoring

  2001cites this paper
• Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond.

  2001cites this paper
• Quantitation of viral load using real-time amplification techniques.

  2001cites this paper
• Developments in the treatment of post-transplant viral disease.

  2001cites this paper
• Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34+ Cells Using the CliniMACS Device

  1999cites this paper